Phathom Pharmaceuticals Inc (PHAT)
$17.72
Performance
- $17.46$17.97$17.72
1.47%
Downside
Day's Volatility :2.84%
Upside
1.39%
- $6.07$18.58$17.72
65.77%
Downside
52 Weeks Volatility :67.36%
Upside
4.63%
Returns
| Period | Phathom Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 67.17% | 5.1% | 0.0% |
6 Months | 94.94% | 4.9% | 0.0% |
1 Year | 36.2% | 16.6% | 0.0% |
3 Years | -49.96% | 13.2% | -22.3% |
Highlights
Market Capitalization | 1.2B |
Book Value | - $3.99 |
Earnings Per Share (EPS) | -5.11 |
Wall Street Target Price | 22.57 |
Profit Margin | 0.0% |
Operating Margin TTM | -1055.43% |
Return On Assets TTM | -54.07% |
Return On Equity TTM | -3489.0% |
Revenue TTM | 9.9M |
Revenue Per Share TTM | 0.17 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -252.1M |
Diluted Eps TTM | -5.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.93 |
EPS Estimate Next Year | -4.5 |
EPS Estimate Current Quarter | -1.38 |
EPS Estimate Next Quarter | -1.34 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 27.37%
Technicals Summary
Sell
Neutral
Buy
Phathom Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Phathom Pharmaceuticals Inc | 63.92% | 94.94% | 36.2% | -49.96% | -27.97% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Phathom Pharmaceuticals Inc | NA | NA | NA | -5.93 | -34.89 | -0.54 | NA | -3.99 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Phathom Pharmaceuticals Inc | Buy | $1.2B | -27.97% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Phathom Pharmaceuticals Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 0.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 119.2%
Institutional Holdings
Medicxi Ventures Management (Jersey) Ltd
12.74%The Carlyle Group Inc
5.97%Amvescap Plc.
5.39%BlackRock Inc
4.99%Jennison Associates LLC
4.71%Ensign Peak Advisors Inc
3.83%
Company Information
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Organization | Phathom Pharmaceuticals Inc |
Employees | 452 |
CEO | Ms. Terrie J. Curran |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$17.72
-1.28%
Keyarch Acquisition Corp
$17.72
-1.28%
Connexa Sports Technologies Inc
$17.72
-1.28%
Us Value Etf
$17.72
-1.28%
First Wave Biopharma Inc
$17.72
-1.28%
Global X Msci Next Emerging
$17.72
-1.28%
Fat Projects Acquisition Corp
$17.72
-1.28%
Capital Link Global Fintech
$17.72
-1.28%
Applied Uv Inc
$17.72
-1.28%